The gross margin stability underscores the high-value specialty and vaccine portfolio, yet the operating margin volatility suggests that quarterly profitability is heavily influenced by the timing of clinical trial expenses and launch-related costs. The 2026Q2 operating margin of 5.7% is a sharp deviation from the 25.5% average of the prior four quarters, indicating that the underlying earning power is better assessed on a trailing twelve-month basis rather than a single quarter. Investors should monitor whether the R&D intensity, which reached 41.7% of revenue in 2026Q2, is a temporary spike or a sustained investment phase that could compress margins further.

The ROIC trajectory shows a clear recovery from the 2024Q3 trough, but the quarterly swings—ranging from 0.5% to 5.4%—indicate that capital efficiency is not yet stable. The improvement is driven by margin recovery rather than asset turnover, which has remained flat at 0.10-0.12, suggesting that GSK is generating higher returns on the same asset base. However, the 2026Q2 dip to 1.0% highlights the sensitivity of ROIC to quarterly earnings volatility, and the company's ability to sustain returns above its cost of capital will depend on the successful commercialization of Arexvy and the HIV portfolio.

The negative CCC is a structural feature of GSK's business model, with DPO far exceeding DSO and DIO, allowing the company to fund operations with supplier credit. The DPO of 666 days in 2026Q2 is notably higher than the 321 days in 2024Q4, suggesting that GSK has extended payment terms with suppliers, which may be a deliberate liquidity strategy. However, such extended payables could strain supplier relationships, and the DSO of 100 days reflects the government and institutional payer mix, which typically has longer collection cycles. The efficiency gains from negative CCC are real, but investors should monitor whether the elongation of DPO is sustainable or a sign of financial pressure.

The deleveraging trend is positive, with D/E declining steadily over the past two years, but the interest coverage ratio is highly volatile, reflecting the earnings swings. The 2026Q2 coverage of 2.95x is concerning, as it suggests that operating income barely covers interest expense in that quarter, though the average coverage over the last four quarters is around 8.5x. The reported D/E of 1.06 may understate true leverage if off-balance-sheet obligations such as pension and lease liabilities are considered, and the Zantac litigation remains a contingent liability that could impact the balance sheet. Investors should monitor the sustainability of the deleveraging path and the adequacy of coverage in low-earnings quarters.

The sub-1.0 current ratio suggests that GSK's short-term liabilities exceed its short-term assets, which could be a liquidity concern if not for the strong operating cash flow generation. The negative CCC and high DPO provide a buffer, as the company effectively uses supplier credit to fund its working capital needs. However, the cash position of $3.1B is modest relative to the $18.1B debt load, and the company relies on refinancing and cash flow to meet obligations. The liquidity position appears adequate under normal conditions, but a severe earnings downturn or an unexpected legal settlement could strain the balance sheet, warranting close monitoring.